Dr Pepper Has Recalled Thousands of Cases of Soda
In perhaps the funniest mislabeling blunder ever, Pepsi Beverages Company is recalling over 19,000 cases of Dr Pepper Zero Sugar products because they actually do, in fact, contain sugar. Whoops!
The Class II recall has a low risk of serious health consequences, but temporary or reversible effects may occur, according to the FDA. To date, no illnesses or adverse reactions have been reported.
While the recall pertains to a large amount of product, the sodas in question were only distributed to retail locations in three states—Florida, South Carolina, and Georgia. The affected products were packaged in 12 fl oz. aluminum cans in both 12-pack and 24-pack cartons and have a "best by" date of February 16, 2026 and product code XXXXRS05165.
While the average consumer might not have issues with accidentally consuming these mislabeled products, the error could indeed pose health risks for people with diabetes or anyone with conditions instructed to monitor their sugar intake. A can of regular Dr Pepper contains 39 grams of sugar, while Dr Pepper Zero Sugar, obviously is meant to contain zero. The latter does, however, contain artificial sweeteners and additional ingredients like aspartame, acesulfame potassium, and sodium phosphate. Good thing we have a doctor in the house.
All recalled products should either be thrown away or returned to your place of purchase.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
AbbVie Secures FDA Approval to Expand Mavyret's Label
AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a . The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), for treating Hepatitis C. The updated approval allows Mavyret—made from the antiviral agents glecaprevir and pibrentasvir—to be used in the US for both adults and children aged three and older with acute or chronic Hepatitis C, provided they do not have cirrhosis or have compensated cirrhosis. Eligible patients can complete treatment in eight weeks. This decision is based on results from a Phase 3 study, which showed the therapy to be safe and effective for acute cases. Mavyret was initially approved in 2017 for newly diagnosed adult Hepatitis C patients. AbbVie Inc. (NYSE:ABBV) is an international biopharmaceutical firm dedicated to creating and providing advanced treatments for challenging health conditions. The company concentrates on key areas such as immunology, cancer, neuroscience, eye care, and aesthetics. Its goal is to improve lives by researching, developing, and offering new therapies that address serious medical needs that currently lack effective solutions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Popular Pistachio Cream Linked Salmonella Outbreak In Multiple States
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." It may be a guava summer, but we're all obsessed with pistachios right now. I mean, have you seen the number of pistachio-flavored products popping up at Costco and Trader Joe's? It's all thanks to Dubai chocolate taking over our taste buds. (Seriously, if you haven't jumped on the pistachio train yet, you need to do so ASAP.) Just make sure you stay away from the cream for now... because it might be contaminated. Yep, tragic news incoming: a multistate Salmonella outbreak has been linked to Emek-brand Pistachio Cream. According to the Food and Drug Administration (FDA), this Turkey-based cream brand is tied to the Salmonella outbreak in Minnesota and New Jersey. So far, four cases have been reported, and one person has been hospitalized. Thankfully, no deaths have been reported at this time. The FDA reports that all affected individuals consumed the cream, with three of them confirming they ate it at the same location. To make matters worse, the Minnesota Department of Health notified the FDA that a sample of the Pistachio Cream tested positive for Salmonella. Yikes. While there hasn't been an official recall yet, it's likely the cream is the source of the outbreak and will be pulled from shelves soon. If you've recently purchased Emek-brand Pistachio Cream and are worried it might be contaminated, here's what you need to know: the affected cream has a use-by date of October 19, 2026, and the product code 241019. If you have this cream in your pantry or refrigerator, it's probably best to toss it and stay safe. Be sure to keep an eye out for any official recall announcements. And if you're really craving pistachio (no judgment here), Amazon has some pretty good dupes, if I do say so myself.$14.99 at at at You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
Yahoo
4 hours ago
- Yahoo
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period. Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year's end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion. A biopharmaceutical research team taking notes in front of a laboratory's microscope. The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential. Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
